The BIO-LIBRA examine evaluated modern outcomes with an implantable cardioverter defibrillator vs. cardiac resynchronization remedy in sufferers with nonischemic cardiomyopathy, with an emphasis on equally enrolling ladies.
Learn Healio’s in-depth protection of the BIO-LIBRA trial.
The trial enrolled 1,000 sufferers at 48 websites throughout the U.S., representing all areas within the nation. Forty-eight % of individuals had been ladies.
Half of the individuals acquired a CRT machine (Biotronik) and half acquired an ICD.
Charges of arrhythmic occasions and loss of life had been widespread in sufferers indicated for ICD or CRT, regardless of adherence to optimum HF medical remedy.
At 3 years, ladies and people who acquired a CRT machine who had nonischemic cardiomyopathy had a decrease threat for the first endpoint of all-cause loss of life or device-treated ventricular tachycardia/ventricular fibrillation occasions.
The outcomes of the BIO-LIBRA examine had been offered at Coronary heart Rhythm 2025.
Learn Healio’s full protection of HRS 2025 right here.
Sources/Disclosures
Collapse
Kutyifa V, et al. Late-breaking scientific trials and science: Medical trials updates and registries (non-ACE). Offered at: Coronary heart Rhythm 2025; April 24-27, 2025; San Diego.
